MediQ*, a Generative AI (artificial intelligence)-based clinical trial trustee and startup that develops tuberculosis diagnostic kits, said on Wednesday that it has attracted seed investment from Accelerator GenExis, the operator of TIPS. The investment is private.

Founded in September 2023, MediQ* is developing AI CRO-related technologies and the tuberculosis diagnostic kit MycoScan using Generative AI technology. It is characterized by the rapid and easy diagnosis of tuberculosis by drastically reducing existing complex procedures and time.

Starting in Korea next year, MediQ* plans to enter global markets such as Vietnam. In general, developing AI technology and commercializing require a lot of time and capital, but MediQ* plans to quickly secure a sales pipeline and continue research and development by selling tuberculosis diagnostic kits.

Tuberculosis is one of the leading causes of death worldwide and has a high incidence, especially in underdeveloped countries. According to MediQ*, its tuberculosis diagnostic kit can reduce the number of tests from three to one, and the diagnosis period can also be shortened from 30 days to 7 days. It is explained that it will be highly competitive in the global market because it is more efficient and cheaper than existing test methods.

Starting with the sale of tuberculosis diagnostic kits, the AI CRO model using Generative AI will greatly improve the inefficiency of the clinical trial process, which takes enormous time and money in the pharmaceutical market, a MediQ* official said.

"MediQ* has a team of outstanding Generative AI technology and medical experts," ZenExis, who made this investment, said. "It is a promising company that can not only enter the global market for tuberculosis diagnosis kits but also lead to a paradigm shift in new drug development through AI CRO."